Alcon's Acquisition of Belkin Vision: A Game-Changer in Glaucoma Treatment
The Swiss-American ophthalmology firm, is set to acquire Israeli glaucoma treatment company Belkin Vision for a total potential sum of $335 million
Alcon, the Swiss-American ophthalmology firm, is set to acquire Israeli glaucoma treatment company Belkin Vision for a total potential sum of $335 million.
Belkin Vision specializes in a laser treatment for glaucoma and gained FDA approval for its device in the US last December. Founded in 2013 as Belkin Laser by ophthalmologist Prof. Michael Belkin, the company aimed to develop a non-contact laser treatment for glaucoma that is both more effective and accessible.
In February 2024, Belkin Vision raised $12.3 million, bringing its total funding to $40 million. Additionally, the company secured a significant $17.5 million grant from the EU.
The deal entails an initial payment of $60 million, with additional milestone payments possible. BioLight Industries, an Israeli ophthalmology investment firm, disclosed the acquisition to the Tel Aviv Stock Exchange. They are poised to receive an immediate payment of NIS 9 million and could potentially gain up to $10.5 million in milestone payments for their 4% stake in Belkin Vision.
